Application of [68Ga]Ga-FAPI-04 PET/CT in the Assessment of Inflammatory Activity in Sjögren's Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Sjögren's syndrome (SS) is a chronic autoimmune disease primarily affecting the salivary and lacrimal glands, leading to symptoms of dryness. Assessing the inflammatory activity is crucial for guiding treatment. Fibroblast activation protein (FAPI) PET is an emerging imaging technique increasingly used for evaluating various inflammations and tumors. Thus this prospective study is going to investigate the uptake characteristics of FAPI PET in Sjögren's syndrome and evaluate its potential in assessing inflammatory activity to guide clinical treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Age 18-80 years;

• Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment.

Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Zhu, MD
13611093752@163.com
13611093752
Backup
Jiarou Wang, MD
ChristinaWang97@163.com
13628477019
Time Frame
Start Date: 2024-07-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 30
Treatments
Experimental: 68Ga-FAPI PET/CT
All patients diagnosed with Sjögren's syndrome underwent 68Ga-FAPI PET/CT.
Sponsors
Leads: Peking Union Medical College Hospital

This content was sourced from clinicaltrials.gov